Market Closed -
Nasdaq
04:00:00 2024-05-28 pm EDT
5-day change
1st Jan Change
3.41
USD
-0.87%
-0.87%
+100.59%
Presentation Operator MessageOperator (Operator)Good day, ladies and gentlemen, and thank you ...
Transcript : Heron Therapeutics, Inc. - Analyst/Investor Day
May. 15
Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 07
CI
Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target
Apr. 23
MT
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024
Mar. 21
CI
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup
Mar. 13
DJ
Sector Update: Health Care Stocks Slipping Late Afternoon
Mar. 13
MT
Heron Therapeutics Shares Soar After Q4 Results Beat
Mar. 13
MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $4, Keeps Buy Rating
Mar. 13
MT
Transcript : Heron Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Mar. 12
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 12
CI
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q4 Revenue $34.2M, vs. Street Est of $31.2M
Mar. 12
MT
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 12
CI
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024
Mar. 12
CI
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef
Jan. 24
DJ
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures
Jan. 24
MT
Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
Jan. 23
CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Boeing 737 Max 9 Grounding
Jan. 08
MT
Heron Therapeutics Unveils Deal to Expand Sales Network for Postoperative Pain Control Anesthetic; Shares Rise Premarket
Jan. 08
MT
Heron Therapeutics, Inc. Enters into Five-Year Distributor Partnership with Crosslink Life Sciences, LLC to Expand the Sales Network Supporting ZYNRELEF
Jan. 07
CI
Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023
Dec. 21
CI
Heron Therapeutics Insider Bought Shares Worth $137,970, According to a Recent SEC Filing
Nov. 17
MT
Needham Trims Price Target on Heron Therapeutics to $4 From $5, Keeps Buy Rating
Nov. 15
MT
Transcript : Heron Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Nov. 14
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q3 Revenue $31.4M, vs. Street Est of $31.8M
Nov. 14
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
More about the company
Last Close Price
3.41
USD
Average target price
6.75
USD
Spread / Average Target
+97.95%
Consensus
1st Jan change
Capi.
+100.59% 514M +54.05% 58.71B -2.02% 41.31B +36.39% 39.2B -10.22% 27.4B +13.42% 26.55B -21.60% 18.98B +2.89% 12.51B +22.40% 11.94B +27.49% 12.08B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1